Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + regorafenib + HAIC
- Development stage
- Phase 2
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Hepatic Arterial Infusion
01
Overview
This combination therapy regimen is being evaluated by the Tianjin Medical University Cancer Institute and Hospital for the treatment of colorectal cancer with liver metastases (CRLM). The regimen integrates the PD-1 checkpoint inhibitor sintilimab, the multi-kinase inhibitor regorafenib, and hepatic arterial infusion chemotherapy (HAIC) utilizing the FOLFOX protocol (oxaliplatin, fluorouracil, and leucovorin). Sintilimab works by restoring T-cell mediated anti-tumor activity, while regorafenib inhibits multiple kinases involved in angiogenesis and oncogenesis. The HAIC component delivers high concentrations of cytotoxic agents directly to the liver via the hepatic artery, aiming to maximize local tumor control and overcome systemic treatment resistance in patients who have failed standard second-line therapies.
- Other names
- sintilimab + regorafenib + hepatic arterial infusion chemotherapysintilimab + regorafenib + FOLFOX-HAIC
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)DNAFGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sintilimab + regorafenib + HAIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + regorafenib + HAIC.